Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy

被引:129
作者
Cai, Yuee [1 ]
Xu, Yingqi [1 ]
Chan, Hon Fai [2 ]
Fang, Xiaobin [1 ]
He, Chengwei [1 ]
Chen, Meiwan [1 ]
机构
[1] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China
[2] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA
基金
中国国家自然科学基金;
关键词
GA; anti-HCC; liver-targeting; delivery systems; SERUM-ALBUMIN NANOPARTICLES; CHARACTERISTICS IN-VITRO; 18-BETA-GLYCYRRHETINIC ACID; CATIONIC LIPOSOMES; INTERCELLULAR COMMUNICATION; ALGINATE NANOPARTICLES; POLYMERIC MICELLES; TARGETED DELIVERY; CELL; DOXORUBICIN;
D O I
10.1021/acs.molpharmaceut.5b00677
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Glycyrrhetinic acid (GA), the main hydrolysate of glycyrrhizic acid extracted from the root of licorice, has been used in hepatocellular carcinoma (HCC) therapy. Particularly, GA as a ligand in HCC therapy has been widely explored in different drug delivery systems, including liposomes, micelles, and nanoparticles. There is considerable interest worldwide with respect to the development of GA-modified drug delivery systems due to the extensive presence of GA receptors on the surface of hepatocyte. Up until now, much work has been focused on developing GA-modified drug delivery systems which bear good liver or hepatocyte-targeted efficiency both in vitro and in vivo. Owing to its contribution in overcoming the limitations of low lipophilicity and poor bioavailability as well as its ability to promote receptor-mediated endocytosis, GA-modified drug delivery systems play an important role in enhancing liver targeting efficacy and thus are focused on the treatment of HCC. Moreover, since GA-modified delivery systems present more favorable pharmacokinetic properties and hepatocyte-targeting effects, they may be a promising formulation for GA in the treatment of HCC. In this review, we will give an overview of GA-modified novel drug delivery systems, paying attention to their efficacy in treating HCC and discussing their mechanism and the treatment effects.
引用
收藏
页码:699 / 709
页数:11
相关论文
共 77 条
[1]  
[Anonymous], DRUG DELIV
[2]  
[Anonymous], 2014, ADV MECH ENG, DOI DOI 10.1155/2014/270749
[3]  
[Anonymous], ARTIF CELLS NANOMED
[4]   Retinoic acid modulates gap junctional intercellular communication in hepatocytes and hepatoma cells [J].
Ara, C ;
Massimi, M ;
Devirgiliis, LC .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (10) :1758-1765
[5]   Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds [J].
Asl, Marjan Nassiri ;
Hosseinzadeh, Hossein .
PHYTOTHERAPY RESEARCH, 2008, 22 (06) :709-724
[6]   Targeted drug delivery to tumors: Myths, reality and possibility [J].
Bae, You Han ;
Park, Kinam .
JOURNAL OF CONTROLLED RELEASE, 2011, 153 (03) :198-205
[7]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[8]   Liver cancer: Approaching a personalized care [J].
Bruix, Jordi ;
Han, Kwang-Hyub ;
Gores, Gregory ;
Llovet, Josep Maria ;
Mazzaferro, Vincenzo .
JOURNAL OF HEPATOLOGY, 2015, 62 :S144-S156
[9]   Hepatocellular carcinoma: Where there is unmet need [J].
Bupathi, Manojkumar ;
Kaseb, Ahmed ;
Meric-Bernstam, Funda ;
Naing, Aung .
MOLECULAR ONCOLOGY, 2015, 9 (08) :1501-1509
[10]   Intercellular communication and human hepatocellular carcinoma [J].
Carruba, G ;
Cocciadiferro, L ;
Bellavia, V ;
Rizzo, S ;
Tsatsanis, C ;
Spandidos, D ;
Muti, P ;
Smith, C ;
Mehta, P ;
Castagnetta, L .
SIGNAL TRANSDUCTION AND COMMUNICATION IN CANCER CELLS, 2004, 1028 :202-212